“If CD12 is an adaptive trial, can the 42 day mo
Post# of 148288
(Total Views: 501)
Posted On: 02/10/2021 11:18:32 AM
“If CD12 is an adaptive trial, can the 42 day mortality be added as an endpoint even through the 75% DSMB recommendation path was not taken?”
In a scenario where the 28 day primary endpoint fails but a reduction in mortality at 42 days is statistically significant, I believe CYDY would still have a strong case for an EUA/full approval. We cannot know for sure, but it’s likely CYDY requested mortality data at 42 days to be included in the unblinded data.
In a scenario where the 28 day primary endpoint fails but a reduction in mortality at 42 days is statistically significant, I believe CYDY would still have a strong case for an EUA/full approval. We cannot know for sure, but it’s likely CYDY requested mortality data at 42 days to be included in the unblinded data.
(10)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼